<DOC>
	<DOCNO>NCT00295932</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide prednisone , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving bortezomib together cyclophosphamide , prednisone , rituximab may effective treatment non-Hodgkin 's lymphoma . PURPOSE : This randomized phase I/II trial study side effect best dose bortezomib give together cyclophosphamide , prednisone , rituximab see well work treat patient relapsed refractory indolent B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Bortezomib , Rituximab , Cyclophosphamide , Prednisone Treating Patients With Relapsed Refractory Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose bortezomib give combination rituximab , cyclophosphamide , prednisone ( R-CP ) patient relapse refractory indolent B-cell lymphoproliferative disorder mantle cell lymphoma . ( phase I ) - Determine frequency duration complete partial response patient treat two different treatment regime . ( phase II ) Secondary - Evaluate progression-free survival , event-free survival , overall survival patient treat regimen . ( phase II ) - Evaluate toxicity profile regimen . OUTLINE : This phase I dose-escalation study bortezomib follow phase II randomize , multicenter study . Patients phase II stratify accord disease ( mantle cell lymphoma vs indolent B-cell lymphoproliferative disorder v transform lymphoma ) . - Phase I : Patients receive cyclophosphamide IV rituximab IV day 1 , oral prednisone day 2-6 , bortezomib IV day 2 7 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cyclophosphamide IV rituximab IV day 1 , oral prednisone day 2-6 , bortezomib IV ( MTD determine phase I ) day 2 , 5 , 9 , 12 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Arm II : Patients receive cyclophosphamide IV rituximab IV day 1 , oral prednisone day 2-6 , bortezomib IV ( MTD determine phase I ) day 2 8 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month , every 4 month 2 year , every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Chronic lymphocytic leukemia ( CLL ) Bcell small lymphocytic leukemia ( SLL ) Any marginal zone lymphoma Grade 13A follicular lymphoma Waldenstrom 's macroglobulinemia Mantle cell lymphoma No transform indolent lymphoma Assessable disease ( phase I ) Measurable disease ( phase I II ) , define ≥ one lesion accurately measure ≥ 1 dimension ≥ 2 cm conventional technique OR ≥ 1 cm spiral CT scan Lymph node measure ≤ 1 cm short axis consider normal Relapsed refractory disease Must receive least 1 prior therapeutic regimen 3 prior conventional cytotoxic therapy regimens No known brain metastasis meningeal disease PATIENT CHARACTERISTICS : Karnofsky performance status &gt; 50 % Absolute neutrophil count &gt; 1,000/mcl ( 500/mcl know lymphomatous involvement ) Platelet count ≥ 50,000/mcl Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ( le 5 mg/dL know history Gilbert 's disease ) AST ALT ≤ 2.5 time ULN ( 4 time ULN liver involvement ) Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 50 mL/min Patients may febrile episode 38.5ºC without evidence active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No New York Heart Association class III IV congestive heart failure No uncontrolled intercurrent illness , include follow : Ongoing active infection Cerebrovascular accident transient ischemic attack within 6 month study entry Unstable angina pectoris Cardiac arrhythmia EKG evidence acute ischemia Psychiatric illness/social situation would limit compliance study requirement No uncontrolled hypertension require active manipulation antihypertensive medication No know active HIV infection No history hypersensitivity bortezomib , boron , mannitol No peripheral neuropathy &gt; grade 2 No malignancy within past 5 year except curatively treat non lifethreatening malignancy , cutaneous basal cell squamous cell carcinoma carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy Prior stem cell transplantation allow Preparative cytoreductive highdose therapy consider 1 prior therapy At least 4 week since prior cytotoxic chemotherapy ( 6 week since prior nitrosoureas mitomycin C ) At least 12 week since prior radioimmunotherapy One prior course comprise tositumomab ibritumomab tiuxetan allow At least 1 week since prior palliative steroid NHL No therapeutic monoclonal antibody ( e.g. , rituximab , tositumomab , ibritumomab , alemtuzumab , etc . ) within 3 month study entry Patients treat monoclonal antibody within 3 month allow provided disease progress therapy AND treatment receive 7 day prior study entry Seven day since prior rituximab ( patient enrol phase I portion ) No major surgery within 4 week study entry No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>